Shanghai Index achieved five consecutive positive momentum yesterday, and closed tenaciously at 3400 points today, closing at 3403.52, up 0.11%. However, excluding the Shanghai Composite Index, the Shanghai and Shenzhen 300 (up 0.16%), the CSI 800 (up 0.06%), and other major indexes closed down in the afternoon. 3,397 individual stocks fell, and 1,784 rose. The transaction volume was 808.46 billion yuan in midday trading, and it is expected to be 1.28 trillion yuan throughout the day. Overall, the index has only increased, but the volume has not been released, and I feel a little bit hard to support it. I am a little worried.
In the sector, banks rose 1.14%, which is also the reason why the Shanghai Stock Exchange is popular, beauty care second, medicine and biology third. National defense and military industry, computers, communications, and electronics, the top four declines. In the near future, it will be a seesaw for consumption, medicine and TMT. There were 56 stocks hitting the daily limit at midday, with no stocks hitting the daily limit. Medicine is mainly innovative drugs, including weight loss drugs, and the progress is gratifying.
Sansheng Pharmaceutical's PD1/VEGF dual anti-anti-anti-anti-anti-anti-Pfizer has a down payment of up to US$1.25 billion, setting a new record for cooperation between innovative drugs and MNC. In terms of weight loss drugs in early May, Novo Nordisk's first quarter 2025 performance showed that the company's total revenue was US$11.01 billion, of which the revenue of the hypoglycemic and weight-loss drug Smegglutide was approximately US$8.484 billion, surpassing Merck K drug (Pembrolizumab, an anti-cancer drug) to become the "drug king", that is, the world's highest-selling drug.
